Previous Section
Treatment of Diabetic Foot Ulcers
Wound Management
This information reflects the FDA's current analysis of available data concerning Regranex Gel. Disseminating this information to the public does not mean that FDA has concluded there is a causal relationship between the use of Regranex Gel and cancer. Nor does it mean that FDA is advising healthcare professionals to discontinue prescribing Regranex Gel. FDA is considering, but has not reached a conclusion, about whether this information warrants any regulatory action. FDA intends to issue updated information when additional data or analysis become available.
While the FDA safety review is ongoing, FDA recommends that healthcare professionals discuss the potential risks and benefits of using Regranex Gel with their patients.
Next: Off-Loading
